-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson reports that its pioneering RIPTAC™ molecule, JNJ-6143, has a 75% tumor remission rate in advanced prostate cancer.

Zhitongcaijing·10/25/2026 07:33:00
Listen to the news
Johnson & Johnson reports that its pioneering RIPTAC™ molecule, JNJ-6143, has a 75% tumor remission rate in advanced prostate cancer.